|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
US4271164A
(en)
|
1979-04-16 |
1981-06-02 |
Warner-Lambert Company |
6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives
|
|
HU196714B
(en)
|
1984-10-04 |
1989-01-30 |
Monsanto Co |
Process for producing non-aqueous composition comprising somatotropin
|
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
PH30995A
(en)
|
1989-07-07 |
1997-12-23 |
Novartis Inc |
Sustained release formulations of water soluble peptides.
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
TW333456B
(en)
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
US6087324A
(en)
|
1993-06-24 |
2000-07-11 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
GB9420168D0
(en)
|
1994-10-06 |
1994-11-23 |
Boots Co Plc |
Therapeutic agents
|
|
AU6242096A
(en)
|
1995-06-27 |
1997-01-30 |
Takeda Chemical Industries Ltd. |
Method of producing sustained-release preparation
|
|
TW448055B
(en)
|
1995-09-04 |
2001-08-01 |
Takeda Chemical Industries Ltd |
Method of production of sustained-release preparation
|
|
JP2909418B2
(ja)
|
1995-09-18 |
1999-06-23 |
株式会社資生堂 |
薬物の遅延放出型マイクロスフイア
|
|
US5980945A
(en)
|
1996-01-16 |
1999-11-09 |
Societe De Conseils De Recherches Et D'applications Scientifique S.A. |
Sustained release drug formulations
|
|
US6264970B1
(en)
|
1996-06-26 |
2001-07-24 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
|
US6419961B1
(en)
|
1996-08-29 |
2002-07-16 |
Takeda Chemical Industries, Ltd. |
Sustained release microcapsules of a bioactive substance and a biodegradable polymer
|
|
CA2217134A1
(en)
|
1996-10-09 |
1998-04-09 |
Sumitomo Pharmaceuticals Co., Ltd. |
Sustained release formulation
|
|
PT839525E
(pt)
|
1996-10-31 |
2004-10-29 |
Takeda Chemical Industries Ltd |
Preparacao de libertacao prolongada
|
|
WO1998027980A2
(en)
|
1996-12-20 |
1998-07-02 |
Takeda Chemical Industries, Ltd. |
Method of producing a sustained-release preparation
|
|
US5891474A
(en)
|
1997-01-29 |
1999-04-06 |
Poli Industria Chimica, S.P.A. |
Time-specific controlled release dosage formulations and method of preparing same
|
|
BR9810385A
(pt)
|
1997-07-01 |
2000-09-05 |
Warner Lambert Co |
Derivados de ácido benzóico 2-(4-bromo ou 4-iodo fenilamino) e sua utilização como inibidores de mek
|
|
JP2910748B2
(ja)
|
1997-11-12 |
1999-06-23 |
日本電気株式会社 |
異質同軸部材の端面の球状加工装置及びその方法
|
|
US6613358B2
(en)
|
1998-03-18 |
2003-09-02 |
Theodore W. Randolph |
Sustained-release composition including amorphous polymer
|
|
KR19990085365A
(ko)
|
1998-05-16 |
1999-12-06 |
허영섭 |
지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
|
|
DE69926914T2
(de)
|
1999-01-13 |
2006-06-29 |
Warner-Lambert Co. Llc |
1-heterozyklus-substituierte diarylaminen
|
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
KR100984595B1
(ko)
|
2002-03-13 |
2010-09-30 |
어레이 바이오파마 인크. |
Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
|
|
WO2003090688A2
(en)
|
2002-04-24 |
2003-11-06 |
Van Andel Research Institute |
Enhancement of human epidermal melanogenesis
|
|
AU2003251661A1
(en)
|
2002-08-06 |
2004-02-25 |
F. Hoffmann-La Roche Ag |
6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
|
|
CN1905873A
(zh)
|
2003-11-19 |
2007-01-31 |
阵列生物制药公司 |
Mek的杂环抑制剂及其使用方法
|
|
EP1742627A4
(en)
|
2004-05-06 |
2009-08-26 |
Plexxikon Inc |
PDE4B HEMMER AND ITS USE
|
|
SI1761528T1
(sl)
|
2004-06-11 |
2008-06-30 |
Japan Tobacco Inc |
5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka
|
|
US7674907B2
(en)
|
2004-07-23 |
2010-03-09 |
Amgen Inc. |
Furanopyridine derivatives and methods of use
|
|
ZA200703912B
(en)
*
|
2004-10-20 |
2008-09-25 |
Serono Lab |
3-arylamino pyridine derivatives
|
|
JP5710855B2
(ja)
|
2005-02-02 |
2015-04-30 |
ネクスジェニクス・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー |
神経線維腫の局所治療
|
|
UA95244C2
(ru)
|
2005-06-22 |
2011-07-25 |
Плексикон, Инк. |
Соединения и способ модулирования активности киназ, и показания для их применения
|
|
SI1934174T1
(sl)
*
|
2005-10-07 |
2011-08-31 |
Exelixis Inc |
Inhibitorji MEK in postopki za njihovo uporabo
|
|
WO2007071951A1
(en)
|
2005-12-21 |
2007-06-28 |
Astrazeneca Ab |
Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
|
|
GB0601962D0
(en)
|
2006-01-31 |
2006-03-15 |
Ucb Sa |
Therapeutic agents
|
|
US7772233B2
(en)
*
|
2006-04-19 |
2010-08-10 |
Merck Serono, S.A. |
Arylamino N-heteroaryl compounds as MEK inhibitors
|
|
GB0616214D0
(en)
|
2006-08-15 |
2006-09-27 |
Ucb Sa |
Therapeutic Agents
|
|
CN101528231A
(zh)
*
|
2006-08-16 |
2009-09-09 |
埃克塞利希斯股份有限公司 |
在癌症的治疗中使用pi3k和mek调控剂
|
|
AU2007286808B2
(en)
|
2006-08-21 |
2012-12-06 |
Genentech, Inc. |
Aza-benzofuranyl compounds and methods of use
|
|
ES2528797T3
(es)
|
2006-08-21 |
2015-02-12 |
Genentech, Inc. |
Compuestos de aza-benzotiofenilo y métodos de uso
|
|
DK2086504T3
(da)
|
2006-10-17 |
2014-04-07 |
Nuvo Res Inc |
Diclofenac-gel
|
|
EP2089359A2
(en)
|
2006-10-31 |
2009-08-19 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors
|
|
PE20081354A1
(es)
|
2006-11-30 |
2008-11-14 |
Genentech Inc |
Compuestos de azaindolilo como inhibidores de mek
|
|
US20090082328A1
(en)
|
2007-05-11 |
2009-03-26 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity
|
|
US20080312307A1
(en)
|
2007-05-25 |
2008-12-18 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors
|
|
JP5421925B2
(ja)
*
|
2007-12-19 |
2014-02-19 |
ジェネンテック， インコーポレイテッド |
５−アニリノイミダゾピリジン及び使用の方法
|
|
CA2708176A1
(en)
|
2007-12-21 |
2009-07-02 |
Genentech, Inc. |
Azaindolizines and methods of use
|
|
GB0801081D0
(en)
|
2008-01-21 |
2008-02-27 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB0801080D0
(en)
|
2008-01-21 |
2008-02-27 |
Ucb Pharma Sa |
Therapeutic agents
|
|
EP2240494B1
(en)
|
2008-01-21 |
2016-03-30 |
UCB Biopharma SPRL |
Thieno-pyridine derivatives as mek inhibitors
|
|
GB0811304D0
(en)
|
2008-06-19 |
2008-07-30 |
Ucb Pharma Sa |
Therapeutic agents
|
|
EP2440204B1
(en)
|
2009-06-12 |
2013-12-18 |
Bristol-Myers Squibb Company |
Nicotinamide compounds useful as kinase modulators
|
|
WO2012040636A2
(en)
|
2010-09-24 |
2012-03-29 |
The Broad Institute, Inc. |
Compounds and methods for treating diseases mediated by protease activated receptors
|
|
MX341471B
(es)
|
2010-11-05 |
2016-08-22 |
Hoffmann La Roche |
Uso de compuestos farmaceuticos activos para el tratamiento de estados patologicos del sistema nervioso central.
|
|
WO2012099968A1
(en)
|
2011-01-19 |
2012-07-26 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating skin cancer associated diseases
|
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
|
WO2012171484A1
(zh)
|
2011-06-17 |
2012-12-20 |
中国中化股份有限公司 |
一种取代氰基苯胺类化合物及制备与应用
|
|
WO2014179785A1
(en)
|
2013-05-03 |
2014-11-06 |
Inscent, Inc. |
Improved honeybee repellents and uses thereof
|
|
US9572828B2
(en)
|
2013-07-18 |
2017-02-21 |
The Board Of Regents Of The University Of Texas System |
Treatment for melanoma
|
|
CN105384738B
(zh)
|
2014-08-21 |
2017-08-29 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
|
|
CN105384754B
(zh)
|
2014-09-02 |
2018-04-20 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
|
|
JP2018535238A
(ja)
|
2015-11-30 |
2018-11-29 |
イグナイタ インコーポレイテッド |
局所製剤
|
|
EP3301094A1
(en)
|
2016-09-30 |
2018-04-04 |
Mutabilis |
Heterocyclic compounds and their use in preventing or treating bacterial infections
|
|
DE102016225694A1
(de)
|
2016-12-21 |
2018-06-21 |
Robert Bosch Gmbh |
Verfahren zur Verstärkung der Bremskraft in einer elektronisch schlupfregelbaren Fahrzeugbremsanlage und elektronisch schlupfregelbare Fahrzeugbremsanlage
|
|
PT3624796T
(pt)
|
2017-05-19 |
2025-06-02 |
Nflection Therapeutics Inc |
Compostos de pirrolopiridina-anilina para tratamento de distúrbios dérmicos
|
|
JP7237941B2
(ja)
|
2017-05-19 |
2023-03-13 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚障害の処置用の融合複素環式芳香族アニリン化合物
|
|
US11395823B2
(en)
|
2018-01-09 |
2022-07-26 |
Duke University |
Topical administration of MEK inhibiting agents for the treatment of skin disorders
|
|
WO2020106308A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Naphthyridinone-aniline compounds for treatment of dermal disorders
|
|
WO2020106304A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Topical formulations
|
|
CA3120351A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
|
|
EP4233834A3
(en)
|
2018-11-20 |
2023-10-25 |
NFlection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks
|
|
WO2020106306A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Cyanoaryl-aniline compounds for treatment of dermal disorders
|
|
WO2020106305A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Thienyl-aniline compounds for treatment of dermal disorders
|
|
JP2024503893A
(ja)
|
2021-01-21 |
2024-01-29 |
エヌフレクション セラピューティクス インコーポレイテッド |
ピロロピリジン－アニリン化合物を調製するための方法
|
|
EP4281055A4
(en)
|
2021-01-21 |
2025-06-18 |
NFlection Therapeutics, Inc. |
CRYSTALLINE FORMS OF A PYRROLOPYRIDINANILINE COMPOUND
|